A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/insulin aspart;   Drug: insulin degludec;   Drug: insulin aspart
Sponsors:   Novo Nordisk;   Novo Nordisk
Active, not recruiting – verified September 2013

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>




11 + eleven =